Neural Noise- Ceribell (Nasdaq: CBLL) announced U.S. FDA 510(k) clearance (K260998) for two new AI algorithm enhancements to its cloud-based Neurology Portal: Epileptiform Abnormality Detection and Artifact Reduction, expanding its Point-of-Care EEG brain-monitoring platform.1
- Artifact Reduction uses AI trained on the company’s own real-world artifact dataset to identify and filter interference beyond traditional filtering methods, simplifying EEG interpretation at the bedside.1
- The clearances were disclosed alongside Ceribell’s Q2 2026 results reporting $28.1 million in quarterly revenue, up 33% year over year, and additional FDA 510(k) clearances for new recorder and headband hardware designs feeding its next-generation platform.2
- CEO Jane Chao said on the earnings call that the algorithm clearances will not be billed separately but are intended to increase clinician stickiness and utilization rather than add incremental device revenue.3
- The company also disclosed a new credit facility providing access to up to $60 million in committed capital ($30 million term loan plus $30 million revolver) to refinance existing debt.2
- This follows Ceribell’s August 3, 2026 CMS New Technology Add-on Payment win for its separate Delirium Monitor System, making the week a run of regulatory and reimbursement milestones for the company’s point-of-care EEG franchise.2